Literature DB >> 32096043

Stress and the Etiopathogenesis of Alzheimer's Disease and Depression.

Ioannis Sotiropoulos1,2, Joana M Silva3,4, Patricia Gomes3,4, Nuno Sousa3,4, Osborne F X Almeida5.   

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with a complex physiopathology whose initiators are poorly defined. Accumulating clinical and experimental evidence suggests a causal role of lifetime stress in AD. This chapter summarizes current knowledge about how chronic stress and its accompanying high levels of glucocorticoid (GC) secretion, trigger the two main pathomechanisms of AD: (i) misprocessing of amyloid precursor protein (APP) and the generation of amyloid beta (Aβ) and (ii) Tau hyperphosphorylation and aggregation. Given that depression is a well-known stress-related illness, and the evidence that depression may precede AD, this chapter also explores neurobiological mechanisms that may be common to depressive and AD pathologies. This review also discusses emerging insights into the role of Tau and its malfunction in disrupting neuronal cascades and neuroplasticity and, thus triggering brain pathology.

Entities:  

Year:  2019        PMID: 32096043     DOI: 10.1007/978-981-32-9358-8_20

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

Review 1.  The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders.

Authors:  Stephen D Ginsberg; Suhasini Joshi; Sahil Sharma; Gianny Guzman; Tai Wang; Ottavio Arancio; Gabriela Chiosis
Journal:  J Neurochem       Date:  2021-10-31       Impact factor: 5.372

Review 2.  Neurobiological Links between Stress, Brain Injury, and Disease.

Authors:  Hanmu Guo; Lexin Zheng; Heng Xu; Qiuyu Pang; Zhiyang Ren; Yuan Gao; Tao Wang
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

3.  Cortisol Reactivity to a physical stressor in Patients with Depression and Alzheimer's disease.

Authors:  Ana Beserra; Bruno Oliveira; Eduardo Portugal; Patrícia Dutra; Jerson Laks; Andrea Deslandes; Helena Moraes
Journal:  Dement Neuropsychol       Date:  2022 Jan-Mar

4.  The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: study protocol.

Authors:  Louise Emsell; Maarten Laroy; Margot Van Cauwenberge; Thomas Vande Casteele; Kristof Vansteelandt; Koen Van Laere; Stefan Sunaert; Jan Van den Stock; Filip Bouckaert; Mathieu Vandenbulcke
Journal:  BMC Psychiatry       Date:  2021-01-28       Impact factor: 3.630

5.  Additive interaction of mid- to late-life depression and cerebrovascular disease on the risk of dementia: a nationwide population-based cohort study.

Authors:  Yoo Jin Jang; Cinoo Kang; Ho Kim; Doh Kwan Kim; Woojae Myung; Shinn-Won Lim; Young Kyung Moon
Journal:  Alzheimers Res Ther       Date:  2021-03-16       Impact factor: 6.982

6.  A Systematic Analysis on the Genes and Their Interaction Underlying the Comorbidity of Alzheimer's Disease and Major Depressive Disorder.

Authors:  Pan Guo; Shasha Chen; Hao Wang; Yaogang Wang; Ju Wang
Journal:  Front Aging Neurosci       Date:  2022-01-20       Impact factor: 5.750

7.  Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence.

Authors:  Taiping Li; Tian Qiu; Yanyan Zeng; Bing Kang; Xianglong Tang; Ning Yang; Hong Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-22       Impact factor: 2.650

8.  Rab35 and glucocorticoids regulate APP and BACE1 trafficking to modulate Aβ production.

Authors:  Viktoriya Zhuravleva; João Vaz-Silva; Mei Zhu; Patricia Gomes; Joana M Silva; Nuno Sousa; Ioannis Sotiropoulos; Clarissa L Waites
Journal:  Cell Death Dis       Date:  2021-12-08       Impact factor: 8.469

9.  Enduring glucocorticoid-evoked exacerbation of synaptic plasticity disruption in male rats modelling early Alzheimer's disease amyloidosis.

Authors:  Yingjie Qi; Igor Klyubin; Tomas Ondrejcak; Neng-Wei Hu; Michael J Rowan
Journal:  Neuropsychopharmacology       Date:  2021-06-29       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.